Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oculis

19.28
-0.2000-1.03%
Post-market: 19.280.00000.00%16:11 EDT
Volume:44.96K
Turnover:863.84K
Market Cap:983.93M
PE:-8.23
High:19.48
Open:19.22
Low:18.98
Close:19.48
Loading ...

Leerink Partners Sticks to Its Buy Rating for Oculis Holding (OCS)

TIPRANKS
·
05 Jun

Oculis Holding Ag : Leerink Partners Raises Target Price to $50.00 From $22.00

THOMSON REUTERS
·
05 Jun

Press Release: Oculis Publishes Results of 2025 Annual General Meeting

Dow Jones
·
05 Jun

2 Brilliant Stocks to Buy With $200 and Hold for 5 Years

Motley Fool
·
14 May

TransMedics Group Stock Is Up 81% in 2025. Can It Climb Even Higher?

Motley Fool
·
13 May

Oculis Holding Is Maintained at Buy by Chardan Capital

Dow Jones
·
09 May

Oculis Holding AG reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Oculis Holding AG Reports Q1 2025 Financial Results

TIPRANKS
·
09 May

Oculis Holding Q1 EPS $(0.69) Misses $(0.43) Estimate

Benzinga
·
09 May

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

GlobeNewswire
·
01 May

TransMedics Group’s OCS Drives Structural Transformation in Liver Transplantation with Increased DCD Liver Utilization

TIPRANKS
·
22 Apr

Oculis Holding Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
17 Apr

Oculis Holding Ag : H.c. Wainwright Raises Target Price to $32 From $29

THOMSON REUTERS
·
17 Apr

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

GlobeNewswire
·
17 Apr

Oculis Holding’s Promising Future: Advancements in Neuroprotection, Dry Eye Treatment, and Diabetic Macular Edema

TIPRANKS
·
17 Apr

Oculis Holding (OCS) Receives a Buy from Bank of America Securities

TIPRANKS
·
16 Apr

Oculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D Day

TIPRANKS
·
16 Apr

Oculis Completes Enrollment in Late-Stage Diabetic Macular Edema Trials

MT Newswires Live
·
10 Apr

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

GlobeNewswire
·
10 Apr

Oculis Down Over 11%, on Track for Largest Percent Decrease Since May 2023 -- Data Talk

Dow Jones
·
05 Apr